keyword
https://read.qxmd.com/read/38607350/bioanalytical-approaches-to-support-the-development-of-antibody-oligonucleotide-conjugate-aoc-therapeutic-proteins
#21
REVIEW
Anthony Murphy, Ryan Hill, Michael Berna
RNA interference (RNAi) is a biological process that evolved to protect eukaryotic organisms from foreign genes delivered by viruses. This process has been adapted as a powerful tool to treat numerous diseases through the delivery of small-interfering RNAs (siRNAs) to target cells to alter aberrant gene expression.Antibody-oligonucleotide conjugates (AOCs) are monoclonal antibodies with complexed siRNA or antisense oligonucleotides (ASOs) that have emerged to address some of the challenges faced by naked or chemically conjugated siRNA, which include rapid clearance from systemic circulation and lack of selective delivery of siRNA to target cells...
April 12, 2024: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://read.qxmd.com/read/38607004/lrrk2-g2019s-promotes-colon-cancer-potentially-via-lrrk2-gsdmd-axis-mediated-gut-inflammation
#22
JOURNAL ARTICLE
Yuhang Wang, Joyce Z Gao, Taylor Sakaguchi, Thorsten Maretzky, Prajwal Gurung, Nandakumar S Narayanan, Sarah Short, Yiqin Xiong, Zizhen Kang
Leucine-rich repeat kinase 2 (LRRK2) is a serine-threonine protein kinase belonging to the ROCO protein family. Within the kinase domain of LRRK2, a point mutation known as LRRK2 G2019S has emerged as the most prevalent variant associated with Parkinson's disease. Recent clinical studies have indicated that G2019S carriers have an elevated risk of cancers, including colon cancer. Despite this observation, the underlying mechanisms linking LRRK2 G2019S to colon cancer remain elusive. In this study, employing a colitis-associated cancer (CAC) model and LRRK2 G2019S knock-in (KI) mouse model, we demonstrate that LRRK2 G2019S promotes the pathogenesis of colon cancer, characterized by increased tumor number and size in KI mice...
March 23, 2024: Cells
https://read.qxmd.com/read/38602417/a-phase-1-study-of-kin-3248-an-irreversible-small-molecule-pan-fgfr-inhibitor-in-patients-with-advanced-fgfr-2-3-driven-solid-tumors
#23
JOURNAL ARTICLE
Benjamin Garmezy, Mitesh J Borad, Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Shumei Kato, Do-Youn Oh, Paul Severson, Betty Y Tam, Cheng Quah, James J Harding
BACKGROUND: Despite efficacy of approved FGFR inhibitors, emergence of polyclonal secondary mutations in the FGFR kinase domain leads to acquired resistance. KIN-3248 is a selective, irreversible, orally bioavailable, small molecule inhibitor of FGFR1-4 that blocks both primary oncogenic and secondary kinase domain resistance FGFR alterations. MATERIALS AND METHODS: A first-in-human, Phase 1 study of KIN-3248 was conducted in advanced solid tumors patients harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822)...
April 11, 2024: Cancer Res Commun
https://read.qxmd.com/read/38597672/cefadroxil-and-cephalexin-pharmacokinetics-and-pharmacodynamics-in-children-with-musculoskeletal-infections
#24
JOURNAL ARTICLE
Andrew S Haynes, Zixuan Wei, Peter Anderson, Marc H Scheetz, Sarah K Parker, Douglas N Fish
Cephalexin, a first-generation cephalosporin, is the first-line oral therapy for children with musculoskeletal infections due to methicillin-susceptible Staphylococcus aureus (MSSA). Cefadroxil, a similar first-generation cephalosporin, is an attractive alternative to cephalexin given its longer half-life. In this study, we describe the comparative pharmacokinetics (PK) and pharmacodynamics (PD) of cephalexin and cefadroxil in children with musculoskeletal infections. Children aged 6 months to 18 years with a musculoskeletal infection were enrolled in a prospective, open-label, crossover PK study and given single oral doses of cefadroxil (50-75 mg/kg up to 2,000 mg) and cephalexin (50 mg/kg up to 1,375 mg)...
April 10, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38596468/lung-microdialysis-and-in-vivo-pk-pd-integration-of-cefquinome-against-actinobacillus-pleuropneumoniae-in-a-porcine-experimental-lung-infection-model
#25
JOURNAL ARTICLE
Yuqin Chen, Min Li, Dehai Su, Shiyu Xiong, Youshu Feng, Qin Deng, Huanzhong Ding
This study aim to explore the application of microdialysis in pharmacokinetic (PK) and pharmacodynamic (PD) integration of cefquinome against Actinobacillus pleuropneumoniae in a porcine experimental lung infection model. The model was established via intratracheal inoculation where average bacterial counts (CFU) in the lungs of infected pigs reached 6.57 log10 CFU/g after 3 h. The PK profiles of unbound cefquinome in lung dialysates were determined following intramuscular injection of single doses of 0...
2024: Frontiers in Veterinary Science
https://read.qxmd.com/read/38596427/ceftriaxone-pharmacokinetics-and-pharmacodynamic-target-attainment-for-three-pediatric-patients-receiving-continuous-kidney-replacement-therapy
#26
JOURNAL ARTICLE
H Rhodes Hambrick, Francisco Cervantes, Min Dong, Peter Tang, Trent Arbough, Alexander A Vinks, Tomoyuki Mizuno, Stuart L Goldstein, Jennifer Kaplan, Sonya Tang Girdwood
Ceftriaxone is used commonly for sepsis, including in children requiring continuous kidney replacement therapy (CKRT). No reports exist of pharmacokinetic (PK) parameters for children receiving ceftriaxone on CKRT. We enrolled children admitted to our pediatric intensive care unit (PICU) who received CKRT for >24 hours and received >1 dose of ceftriaxone while on and off CKRT. We measured free ceftriaxone -concentrations from residual blood samples then used Bayesian estimation with PK modeling software to generate concentration-time profiles and determine PK parameters and the percentage of time free ceftriaxone concentrations were above 1× or 4× MIC (% f T >MIC)...
April 2024: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
https://read.qxmd.com/read/38595961/lenvatinib-combined-with-the-pd-1-inhibitor-camrelizumab-in-the-treatment-of-primary-liver-cancer-caused-hemorrhagic-exfoliative-gastritis
#27
Hong Chen, Zihua Wang, Chunhua Wang
INTRODUCTION: Patients with advanced primary liver cancer often lose the opportunity for surgery when they are found, and the treatment options are limited. Lenvatinib, as a multi-target tyrosine kinase inhibitor, has been used as the first-line treatment for advanced liver cancer. Immune checkpoint inhibitors, such as programmed cell death protein 1 inhibitors, have been successfully used in advanced or metastatic liver cancer. CASE PRESENTATION: We report a case of combined lenvatinib and the programmed cell death protein 1 inhibitor camrelizumab in the treatment of primary liver cancer, in which the rare complication of full-thickness gastric mucosa exfoliation occurred...
2024: Case Reports in Oncology
https://read.qxmd.com/read/38595918/dosing-optimization-of-rituximab-for-primary-membranous-nephropathy-by-population-pharmacokinetic-and-pharmacodynamic-study
#28
JOURNAL ARTICLE
Hao Liang, Zhenling Deng, Shu Niu, Weijie Kong, Yang Liu, Song Wang, Haiyan Li, Yue Wang, Danxia Zheng, Dongyang Liu
Primary membranous nephropathy (PMN) is the most common cause for adult nephrotic syndrome. Rituximab has demonstrated promising clinical efficacy by random controlled trials and the off-label use is widely adopted in PMN. However, the standard dosage is borrowed from B cell lymphoma treatment with far more antigens and is oversaturated for PMN treatment, accompanied with additional safety risk and unnecessary medical cost. More than 15% serious adverse events were observed under standard dosage and low dose therapies were explored recently...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38594870/-ge-gen-decoction-alleviates-primary-dysmenorrhoea-symptoms-in-a-rat-model
#29
JOURNAL ARTICLE
Yazhen Xie, Haifeng Xu, Zhijuan Gu
BACKGROUND: Existing treatments for primary dysmenorrhoea (PD), such as NSAIDs, impart side effects. Ge-Gen decoction (GGD), a traditional Chinese medicine, has shown promise in treating PD, but its exact mechanisms remain unclear. Here, we aimed to investigate the efficiency of GGD in alleviating PD using a rat model to understand its precise mechanism of action. METHODS: We established a rat model of dysmenorrhoea induced by oestradiol and oxytocin. The PD rats were administered GGD or Ibuprofen (positive control) intragastrically once daily for seven consecutive days...
December 2024: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
https://read.qxmd.com/read/38594687/radiotherapy-combined-with-anti-pd-1-and-tki-for-primary-cardiac-angiosarcoma-considering-the-joint-assessment-of-tlss-and-pd-l1-a-case-report
#30
JOURNAL ARTICLE
Shuzhe Deng, Xinxin Yang, Lin He, Qian Zhang, Chunbo Zhao, Hongxue Meng
BACKGROUND: Primary cardiac angiosarcoma(PCA) has a low incidence rate and poor prognosis. Currently, no unified clinical treatment standards are available. CASE PRESENTATION: We report the case of a 48-year-old man presenting chest tightness, breathlessness, and dyspnea. Imaging and postoperative histopathologic studies confirmed PCA and that the tumor had invaded the entire right atrium. The patient developed progressive disease (PD) during postoperative radiotherapy...
April 9, 2024: Journal of Cardiothoracic Surgery
https://read.qxmd.com/read/38594551/exploring-key-genes-and-pathways-associated-with-sex-differences-in-autism-spectrum-disorder-integrated-bioinformatic-analysis
#31
JOURNAL ARTICLE
Himani Nautiyal, Akanksha Jaiswar, Prabhash Kumar Jha, Shubham Dwivedi
Autism spectrum disorder (ASD) is a heterogenous neurodevelopmental disorder marked by functional abnormalities in brain that causes social and linguistic difficulties. The incidence of ASD is more prevalent in males compared to females, but the underlying mechanism, as well as molecular indications for identifying sex-specific differences in ASD symptoms remain unknown. Thus, impacting the development of personalized strategy towards pharmacotherapy of ASD. The current study employs an integrated bioinformatic approach to investigate the genes and pathways uniquely associated with sex specific differences in autistic individuals...
April 9, 2024: Mammalian Genome: Official Journal of the International Mammalian Genome Society
https://read.qxmd.com/read/38593348/translational-and-therapeutic-evaluation-of-ras-gtp-inhibition-by-rmc-6236-in-ras-driven-cancers
#32
JOURNAL ARTICLE
Jingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, Yingyun Wang, Matthew Holderfield, Ida Aronchik, Ian P Winters, Zeena Salman, Cristina Blaj, Marie Menard, Jens Brodbeck, Zhe Chen, Xing Wei, Michael J Rosen, Yevgeniy Gindin, Bianca J Lee, James W Evans, Stephanie Chang, Zhican Wang, Kyle J Seamon, Dylan Parsons, James Cregg, Abby Marquez, Aidan C A Tomlinson, Jason K Yano, John E Knox, Elsa Quintana, Andrew J Aguirre, Kathryn C Arbour, Abby Reed, W Clay Gustafson, Adrian L Gill, Elena S Koltun, David Wildes, Jacqueline A M Smith, Zhengping Wang, Mallika Singh
UNLABELLED: RAS-driven cancers comprise up to 30% of human cancers. RMC-6236 is a RAS(ON) multi-selective noncovalent inhibitor of the active, GTP-bound state of both mutant and wild-type variants of canonical RAS isoforms with broad therapeutic potential for the aforementioned unmet medical need. RMC-6236 exhibited potent anticancer activity across RAS-addicted cell lines, particularly those harboring mutations at codon 12 of KRAS. Notably, oral administration of RMC-6236 was tolerated in vivo and drove profound tumor regressions across multiple tumor types in a mouse clinical trial with KRASG12X xenograft models...
April 9, 2024: Cancer Discovery
https://read.qxmd.com/read/38591006/isg12a-promotes-immunotherapy-of-hbv-associated-hepatocellular-carcinoma-through-blocking-trim21-akt-%C3%AE-catenin-pd-l1-axis
#33
JOURNAL ARTICLE
Rilin Deng, Renyun Tian, Xinran Li, Yan Xu, Yongqi Li, Xintao Wang, Huiyi Li, Luoling Wang, Biaoming Xu, Di Yang, Songqing Tang, Binbin Xue, Chaohui Zuo, Haizhen Zhu
Hepatitis B virus (HBV) infection generally elicits weak type-I interferon (IFN) immune response in hepatocytes, covering the regulatory effect of IFN-stimulated genes. In this study, low level of IFN-stimulated gene 12a (ISG12a) predicted malignant transformation and poor prognosis of HBV-associated hepatocellular carcinoma (HCC), whereas high level of ISG12a indicated active NK cell phenotypes. ISG12a interacts with TRIM21 to inhibit the phosphorylation activation of protein kinase B (PKB, also known as AKT) and β-catenin, suppressing PD-L1 expression to block PD-1/PD-L1 signaling, thereby enhancing the anticancer effect of NK cells...
April 19, 2024: IScience
https://read.qxmd.com/read/38587857/discovery-of-novel-heterotricyclic-compounds-as-dna-dependent-protein-kinase-dna-pk-inhibitors-with-enhanced-chemosensitivity-oral-bioavailability-and-the-ability-to-potentiate-cancer-immunotherapy
#34
JOURNAL ARTICLE
Binbin Cheng, Yaru Shi, Chuxiao Shao, Shuanghu Wang, Zhenhong Su, Jin Liu, Yingxing Zhou, Xiaoting Fei, Wei Pan, Jianjun Chen, Yiyu Lu, Jian Xiao
In this work, a novel series of heterotricyclic DNA-PK inhibitors were rationally designed, synthesized, and assessed for their biological activity. In the DNA-PK biochemical assay, most compounds displayed potent enzymatic activity, with IC50 values between 0.11 and 71.5 nM. Among them, SK10 exhibited the most potent DNA-PK-inhibitory activity (IC50 = 0.11 nM). Studies of the mechanism of action indicated that SK10 could lower γH2A.X expression levels and demonstrate optimal synergistic antiproliferative activity against Jurkat cells (IC50 = 25 nM) when combined with doxorubicin...
April 8, 2024: Journal of Medicinal Chemistry
https://read.qxmd.com/read/38587080/prophylactic-efficacy-of-an-intranasal-spray-with-2-synergetic-antibodies-neutralizing-omicron
#35
JOURNAL ARTICLE
Xinghai Zhang, Feiyang Luo, Huajun Zhang, Hangtian Guo, Junhui Zhou, Tingting Li, Shaohong Chen, Shuyi Song, Meiying Shen, Yan Wu, Yan Gao, Xiaojian Han, Yingming Wang, Chao Hu, Xiaodong Zhao, Huilin Guo, Dazhi Zhang, Yuchi Lu, Wei Wang, Kai Wang, Ni Tang, Tengchuan Jin, Menglu Ding, Shuhui Luo, Cuicui Lin, Tingting Lu, Bingxia Lu, Yang Tian, Chengyong Yang, Guofeng Cheng, Haitao Yang, Aishun Jin, Xiaoyun Ji, Rui Gong, Sandra Chiu, Ailong Huang
BACKGROUNDAs Omicron is prompted to replicate in the upper airway, neutralizing antibodies (NAbs) delivered through inhalation might inhibit early-stage infection in the respiratory tract. Thus, elucidating the prophylactic efficacy of NAbs via nasal spray addresses an important clinical need.METHODSThe applicable potential of a nasal spray cocktail containing 2 NAbs was characterized by testing its neutralizing potency, synergetic neutralizing mechanism, emergency protective and therapeutic efficacy in a hamster model, and pharmacokinetics/pharmacodynamic (PK/PD) in human nasal cavity...
April 8, 2024: JCI Insight
https://read.qxmd.com/read/38585465/ampk-signaling-pathway-as-a-potential-therapeutic-target-for-parkinson-s-disease
#36
REVIEW
Seyed Zanyar Athari, Fereshteh Farajdokht, Rana Keyhanmanesh, Gisou Mohaddes
Parkinson's disease (PD) is the second most common neurodegenerative disease caused by the loss of dopaminergic neurons. Genetic factors, inflammatory responses, oxidative stress, metabolic disorders, cytotoxic factors, and mitochondrial dysfunction are all involved in neuronal death in neurodegenerative diseases. The risk of PD can be higher in aging individuals due to decreased mitochondrial function, energy metabolism, and AMP-activated protein kinase (AMPK) function. The potential of AMPK to regulate neurodegenerative disorders lies in its ability to enhance antioxidant capacity, reduce oxidative stress, improve mitochondrial function, decrease mitophagy and macroautophagy, and inhibit inflammation...
March 2024: Advanced Pharmaceutical Bulletin
https://read.qxmd.com/read/38585433/effects-of-metformin-on-jnk-signaling-pathway-and-pd-l1-expression-in-triple-negative-breast-cancer
#37
JOURNAL ARTICLE
Ruibin Wang, Yanjie Zhao
BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Metformin has been shown to have the potential to inhibit the proliferation of malignant cells. This study aimed to investigate the regulatory effect of metformin on the expression of programmed death protein ligand 1(PD-L1) and mechanisms in TNBC. METHODS: Mouse breast cancer cell line 4T1 was co-cultured with metformin, and the effect of metformin on cell proliferation was detected by MTT assay...
2024: Cancer Management and Research
https://read.qxmd.com/read/38584542/suppression-of-glioblastoma-stem-cell-potency-and-tumor-growth-via-lrrk2-inhibition
#38
JOURNAL ARTICLE
Saewhan Park, Kyung-Hee Kim, Yun-Hee Bae, Young Taek Oh, Hyemi Shin, Hyung Joon Kwon, Chan Il Kim, Sung Soo Kim, Hwan-Geun Choi, Jong Bae Park, Byoung Dae Lee
Leucine-rich repeat kinase 2 (LRRK2), a large GTP-regulated serine/threonine kinase, is well-known for its mutations causing late-onset Parkinson's disease. However, the role of LRRK2 in glioblastoma (GBM) carcinogenesis has not yet been fully elucidated. Here, we discovered that LRRK2 was overexpressed in 40% of GBM patients, according to tissue microarray analysis, and high LRRK2 expression correlated with poor prognosis in GBM patients. LRRK2 and stemness factors were highly expressed in various patient-derived GBM stem cells, which are responsible for GBM initiation...
April 8, 2024: International Journal of Stem Cells
https://read.qxmd.com/read/38584166/personalized-neoantigen-vaccine-and-pembrolizumab-in-advanced-hepatocellular-carcinoma-a-phase-1-2-trial
#39
JOURNAL ARTICLE
Mark Yarchoan, Edward J Gane, Thomas U Marron, Renzo Perales-Linares, Jian Yan, Neil Cooch, Daniel H Shu, Elana J Fertig, Luciane T Kagohara, Gabor Bartha, Josette Northcott, John Lyle, Sarah Rochestie, Joann Peters, Jason T Connor, Elizabeth M Jaffee, Ildiko Csiki, David B Weiner, Alfredo Perales-Puchalt, Niranjan Y Sardesai
Programmed cell death protein 1 (PD-1) inhibitors have modest efficacy as a monotherapy in hepatocellular carcinoma (HCC). A personalized therapeutic cancer vaccine (PTCV) may enhance responses to PD-1 inhibitors through the induction of tumor-specific immunity. We present results from a single-arm, open-label, phase 1/2 study of a DNA plasmid PTCV (GNOS-PV02) encoding up to 40 neoantigens coadministered with plasmid-encoded interleukin-12 plus pembrolizumab in patients with advanced HCC previously treated with a multityrosine kinase inhibitor...
April 7, 2024: Nature Medicine
https://read.qxmd.com/read/38583268/frontiers-in-sarcopenia-advancements-in-diagnostics-molecular-mechanisms-and-therapeutic-strategies
#40
REVIEW
Dequan Liu, Shijin Wang, Shuang Liu, Qifei Wang, Xiangyu Che, Guangzhen Wu
The onset of sarcopenia is intimately linked with aging, posing significant implications not only for individual patient quality of life but also for the broader societal healthcare framework. Early and accurate identification of sarcopenia and a comprehensive understanding of its mechanistic underpinnings and therapeutic targets paramount to addressing this condition effectively. This review endeavors to present a cohesive overview of recent advancements in sarcopenia research and diagnosis. We initially delve into the contemporary diagnostic criteria, specifically referencing the European Working Group on Sarcopenia in Older People (EWGSOP) 2 and Asian Working Group on Sarcopenia (AWGS) 2019 benchmarks...
April 6, 2024: Molecular Aspects of Medicine
keyword
keyword
978
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.